Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children with confirmed SCA who participated in the NOHARM study of hydroxyurea at the Mulago Hospital Sickle Cell Clinic (MHSCC), will be eligible for the MTD study after completing both 12-months of blinded study treatment and then an additional 12-months of open-label hydroxyurea for the second year of the study.~* The age range for enrollment into NOHARM, which began in 2014, was 1-4 years. Therefore, the children who will be enrolled in the follow up MTD study will be 3-6 years of age.~Exclusion Criteria:~* Not willing to come for all scheduled clinical visits or accept randomization

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 72 Months
- Healthy Volunteers: f

Study Arms:
- MTD Dose Escalation (Type: EXPERIMENTAL): Maximum tolerated dose of Hydroxyurea, 25-30 mg/kg/day
- Fixed Dose (Type: ACTIVE_COMPARATOR): Fixed dose of Hydroxyurea, 20 mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).